🇧🇪 ARGX.BR — argenx SE

Salud Compra fuerte
← Volver

Precio actual

815,80 EUR

Máx. histórico

912,40

64 días

Caída desde máximo

-10,59%

Rango 52 semanas

568,40 – 925,00

Variación hoy

+0,03%

Cierre anterior

815,60

Rango de hoy

788,80 – 815,80

Volumen hoy

102.849

Peor caída histórica

-39,26%

21/07/2023 → 21/12/2023

Recuperado en 262 días

Volatilidad anualizada ⓘ

43,77%

Información
Nombre completo
argenx SE
Divisa
EUR
Mercado
Brussels
Sector
Salud
Industria
Biotechnology
Empleados
1.863
PER ⓘ
32,83 (puede no estar actualizado)
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
1.005,32 EUR (puede no estar actualizado)
Primera cotización
10/07/2014
Precio actualizado
hace 1 día
Sobre la empresa

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
13/02/2017 16,00 16,00 15,65 15,80 -0,38% 2,19% 4.553
10/02/2017 15,66 15,93 15,33 15,86 +0,95% 3,83% 26.980
09/02/2017 15,66 15,94 15,65 15,71 +0,83% 1,85% 16.478
08/02/2017 16,46 16,46 15,25 15,58 -3,83% 7,35% 25.590
07/02/2017 16,26 16,44 16,20 16,20 -0,92% 1,48% 6.296
06/02/2017 16,25 16,48 16,17 16,35 +1,55% 1,91% 7.094
03/02/2017 16,05 16,34 16,05 16,10 +0,50% 1,81% 7.175
02/02/2017 16,47 16,47 16,01 16,02 -1,23% 2,79% 4.118
01/02/2017 16,10 16,48 16,06 16,22 +1,37% 2,61% 5.886
31/01/2017 16,05 16,10 16,00 16,00 -0,31% 0,62% 4.650
30/01/2017 16,20 16,20 16,05 16,05 -0,37% 0,93% 3.179
27/01/2017 16,47 16,47 16,11 16,11 -0,56% 2,19% 9.099
26/01/2017 16,46 16,46 16,15 16,20 +0,00% 1,88% 12.667
25/01/2017 16,48 16,48 16,20 16,20 -0,12% 1,70% 3.534
24/01/2017 16,10 16,44 16,06 16,22 +1,00% 2,36% 7.388
23/01/2017 16,35 16,35 16,06 16,06 +0,00% 1,77% 5.635
20/01/2017 16,01 16,28 16,01 16,06 -0,06% 1,69% 1.448
19/01/2017 16,49 16,49 16,07 16,07 -0,86% 2,55% 3.863
18/01/2017 16,67 16,67 16,21 16,21 -1,22% 2,76% 4.852
17/01/2017 16,75 16,76 16,25 16,41 +0,67% 3,04% 5.199
16/01/2017 16,53 16,55 16,30 16,30 -0,61% 1,51% 3.789
13/01/2017 16,53 16,65 16,40 16,40 -0,79% 1,51% 105.628
12/01/2017 16,39 16,55 16,35 16,53 +1,79% 1,22% 4.142
11/01/2017 16,36 16,60 16,01 16,24 +1,31% 3,61% 20.452
10/01/2017 16,00 16,10 16,00 16,03 -0,31% 0,63% 2.576
09/01/2017 16,31 16,67 16,08 16,08 -3,48% 3,62% 4.053
06/01/2017 16,68 16,80 16,36 16,66 -0,24% 2,64% 13.513
05/01/2017 16,26 16,70 15,73 16,70 +2,45% 5,97% 64.991
04/01/2017 16,26 16,40 16,25 16,30 +0,31% 0,92% 1.888
03/01/2017 16,15 16,45 16,15 16,25 +0,06% 1,86% 2.188